Congratulations to Accelmed, the equity investors, who backed SoniVie, a startup company based in Israel that’s made a breakthrough treatment device for pulmonary arterial hypertension (PAH). Of course, we owe a huge round of applause to SoniVie! SoniVie has successfully finished its first two procedures in human patients who participated in the clinical trial.
At the center of all the buzz is a catheter SoniVie developed, called TIVUS, which will be used therapeutically. TIVUS stands for: Therapeutic Intra-Vascular Ultrasound.
TIVUS looks to be a unique catheter—a targeted treatment for people living with PAH, a progressive and terminal disease that has no cure. After diagnosis, most patients live, on average, about five years. What’s looking so promising about TIVUS is that, when it’s introduced into the pulmonary artery during catheterization, it selectively targets and halts certain nerve activity, but otherwise, does not impact or damage surrounding tissues.
Scientists and leading surgeons believe this may, in fact, modify and slow the progression of the disease!
If you would like to read more about TIVUS, you can find it here.
